Parathyroid hormone is associated with prostate cancer

Abstract Background The present study investigated the association of serum parathyroid hormone (PTH), vitamin D, and calcium levels with prostate cancer (CaP). Methods The study population consisted of an experimental group [459 patients including 216 CaP and 243 benign prostate hyperplasia (BPH)] and a prostatectomy group (47 radical prostatectomy patients). Patients with serum creatinine levels >1.4 mg/dl, parathyroid disease, and/or PTH levels Results Mean PTH levels were 41.67 ± 28.82 and 27.06 ± 17.32 pg/ml in the CaP and BPH groups, respectively (p 20 ng/ml), Gleason score (≤7 or ≥8), and stage (≤T3 or ≥T4), there was no significant difference in PTH levels between the two groups. Mean postoperative PTH levels (26.93 ± 13.58 pg/ml) were significantly lower than preoperative PTH levels (36.71 ± 21.04 pg/ml) in the same radical prostatectomy patients. Conclusion Serum PTH levels were higher in CaP than in BPH patients, and decreased significantly after radical prostatectomy. The present results suggest an association between serum PTH and CaP. Further large cohort studies are necessary to validate the present data.